Phaseline

Targets › HSD11B1

HSD11B1 (11-beta-hydroxysteroid dehydrogenase 1): drug programs, companies and trials

3 programs from 3 companies in 8 trials: 4 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Psychiatry, Genitourinary; next expected readout Nov 2027.

Controls the reversible conversion of biologically active glucocorticoids such as cortisone to cortisol, and 11-dehydrocorticosterone to corticosterone in the presence of NADP(H). Participates in the corticosteroid receptor-mediated anti-inflammatory response, as well as metabolic and homeostatic processes. (UniProt, P28845)

Open in Phaseline: the race on HSD11B1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Opevesostat (MK-5684)
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt
HSD11B1, ARPhase 3Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant …Nov 2027
Sparrow Pharmaceuticalsclofutriben
11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) inhibitor
HSD11B1Phase 2Type 2 Diabetes; Moderate Renal ImpairmentDec 2027
Philipps University MarburgEnoxolone
11β-hydroxysteroid dehydrogenase inhibitor
HSD11B1Phase 1Unipolar Depression–

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Prostate Cancer Metastatic (1) Malignant Neoplasm (1) Prostatic Neoplasms, Castration-Resistant (1) Castration-Resistant Prostatic Cancer (1) Unipolar Depression (1) Type 2 Diabetes (1) Moderate Renal Impairment (1)

Modalities

small molecule (3)

Companies

Merck & Co. (MSD) (1) Philipps University Marburg (1) Sparrow Pharmaceuticals (1)

Related targets

AR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.